Yahoo Finance

Oncocyte Announces Definitive Agreement to Acquire Chronix Biomedical, Inc.

IRVINE, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points ...
EurekAlert!

Chronix Biomedical's serum DNA assays monitor disease activity and treatment response in MS

San Jose, California, April 6, 2010 – Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease ...
technologynetworks

Chronix Biomedical’s DNA Blood Tests Detect Breast and Prostate Cancer with 92% Sensitivity and 100% Specificity

Chronix Biomedical today reported new data further demonstrating that its DNA blood tests have the potential to accurately detect early stage breast and prostate cancers. Chronix’s proprietary ...
technologynetworks

New Concerns About Mad Cow Disease Highlight Importance of Chronix Blood Test that can Detect BSE Before Symptoms Appear

Chronix Biomedical has announced that its CEO, Dr. Howard Urnovitz, will discuss the company’s DNA biomarker technology for the detection of bovine spongiform encephalopathy (BSE), or mad cow disease, ...
Business Wire

Newly Published Data Shows Chronix Biomedical’s Serum DNA Assays Can Monitor Disease Activity and Treatment Response in Multiple Sclerosis

SAN JOSE, Calif.--(BUSINESS WIRE)--Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease ...
Nasdaq

Oncocyte Enters the Rapidly Growing Immune Therapy Monitoring Market with the Closing of the Acquisition of Chronix Biomedical, Inc.

Oncocyte’s technologies may provide more precision to the selection of appropriate immune therapies and monitoring for treatment response in real time allowing physicians to personalize treatment more ...
EurekAlert!

Study shows Chronix technology using serum DNA can identify early presence of disease

San Jose, California, June 23, 2009 – Chronix Biomedical today reported that a new study in a peer-reviewed journal further confirms the potential diagnostic and prognostic utility of using ...
Business Wire

Chronix Biomedical Study Demonstrates Its Blood Test Can Predict Response to Cancer Immunotherapy

SAN JOSE, Calif. & GÖTTINGEN, Germany--(BUSINESS WIRE)--Chronix Biomedical, Inc., a developer of novel cancer blood-based molecular diagnostics, announces the publication of positive results of a ...
VentureBeat

Diagnostics firm Chronix busts out of stealth, looks for cash

Chronix Biomedical, a diagnostic test development company that has operated mostly in secret since its 2000 inception, has finally come out of its shell — publishing information on its product in ...
NBC News

Chronix Biomedical and Hemispherx Biopharma Jointly File Patent Application for a Blood Test for Chronic Fatigue Syndrome (CFS)

Get exclusive reporting, live Q&As and ad-free reading. Hemispherx and Chronix Plan Studies to Validate Technology as a Potential Diagnostic Test for CFS SAN JOSE, Calif., March 3, 2011 (GLOBE ...
Medindia

Chronix Technology Using Serum DNA may Identify Early Presence of Disease

The potential diagnostic and prognostic utility of using circulating fragments of DNA to detect early stage disease is further confirmed by a new study in a peer-reviewed journal, Chronix Biomedical ...